stockrowHemab Therapeutics Holdings, Inc. (COAG) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Hemab Therapeutics Holdings, Inc. COAG 48.60 +6.65%
- Recursion Pharmaceuticals, Inc. RXRX 3.52 +0.57%
Hemab Therapeutics Holdings, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Hemab Therapeutics Holdings, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.2B and $2.1B). Hemab Therapeutics Holdings, Inc. has the higher net margin (0.00% vs −697.1%) and the higher return on invested capital (0.00% vs −88.5%). Across the 11 metrics below, Hemab Therapeutics Holdings, Inc. leads on 9 and Recursion Pharmaceuticals, Inc. on 2.
Valuation
Profitability
| Metric | COAG | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 29.21% | 68.51% |
| Operating margin | 0.00% | (725.44%) | 0.00% |
| Net margin | 0.00% | (697.13%) | 0.00% |
| Free cash flow margin | 0.00% | (460.89%) | 0.00% |
| Return on equity | 0.00% | (48.72%) | (51.96%) |
| Return on assets | (31.79%) | (36.29%) | (46.06%) |
| Return on invested capital | 0.00% | (88.54%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack